Full-Time

Senior Account Executive

Pathology Sales-Oncology Division

Posted on 6/19/2025

Guardant Health

Guardant Health

1,001-5,000 employees

Develops blood tests for cancer diagnostics

No salary listed

Senior, Expert

Boston, MA, USA

Category
Field Sales
Sales & Account Management
Biology & Biotech
Required Skills
Salesforce
Requirements
  • 7+ years in account management in pathology sales, diagnostics, lab services, or oncology-related roles (highly prefer experience selling in diagnostics directly to Pathologists)
  • Deep knowledge of FFPE Tissue based NGS / CGP testing
  • Deep knowledge of pathology workflows, molecular diagnostics, or oncology therapeutic areas.
  • A customer-first mindset and the ability to influence clinical decision-makers with empathy and clarity.
  • Demonstrated track record of delivering results in a consultative sales environment.
  • Familiarity with pathology billing, reimbursement, and lab contracting a plus.
  • Proficiency with CRM tools (Salesforce preferred) and Microsoft Office Suite.
  • Ability to travel >50% within your territory.
Responsibilities
  • Drive overall 360 tissue volume in assigned / overlapping regions.
  • Promote the adoption of precision oncology diagnostics and the Guardant Health testing portfolio with the focus on driving 360 tissue.
  • Execute Laboratory Service Agreements and break down ordering barriers in accounts.
  • Negotiate pricing agreements based on a tied pricing schedule and facilitate escalation of pricing exceptions outside of guardrails.
  • Work with the KAD and KAM overlapping the region on higher level partnership agreements and contracts.
  • Present Guardant services and solutions to C-level executives in hospitals and pathology departments.
  • Target and close new business opportunities for tissue testing in pathology accounts in the community oncology setting and at academic cancer centers.
  • Manage and expand existing accounts to ensure client satisfaction and retention.
  • Collaborate with internal teams (medical, billing, operations) to resolve client issues.
  • Forecast sales and manage account pipelines via CRM.
  • Facilitate obtaining FFPE tissue processing agreements, where needed, and agreements for reimbursement of slide processing / cutting in place with the hospitals and or path labs.
  • Establish and nurture long-term relationships with pathologists, oncologists, hospital administrators, and oncology and pathology department staff.
  • Deliver in-field training on pathology workflows, diagnostic tests, and technology solutions.
  • Build clinical consensus on complex molecular diagnostic pathways.
  • Train healthcare staff on EMR-integrated oncology workflows.
  • Work in coordination with multiple cross functional partners (Oncology Sales Team, Medical Affairs, IT, Customer Service, and Key Accounts).
  • Collaborate with leading healthcare professionals in oncology and pathology innovation.
Desired Qualifications
  • Familiarity with pathology billing, reimbursement, and lab contracting a plus.
  • Advanced degree or clinical/lab background a plus.

Guardant Health specializes in blood-based tests that provide essential information for cancer treatment and management. Their products are designed to assist patients at various stages of cancer, from early detection to managing advanced disease. The company develops and sells diagnostic tests that utilize blood samples to detect, monitor, and guide treatment decisions for cancer patients. Their main product, Guardant360, is FDA-approved and commonly used to help inform treatment choices for those with advanced cancer. Guardant Health is also working on expanding its offerings to include tests for early-stage cancer detection and monitoring for recurrence. By focusing on non-invasive and data-rich diagnostics, the company aims to enhance patient outcomes and lessen the overall impact of cancer.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Guardant Health's collaboration with Pfizer could boost revenue through new cancer therapies.
  • The launch of hereditary cancer testing taps into the growing genetic testing market.
  • Participation in ASMM may accelerate adoption of their diagnostic technologies.

What critics are saying

  • Increased competition from Caris Life Sciences may impact Guardant Health's market share.
  • Rapid technological advancements could outpace Guardant Health's product integration capabilities.
  • Expansion into hereditary cancer testing may face regulatory scrutiny and compliance challenges.

What makes Guardant Health unique

  • Guardant Health specializes in blood-based tests for cancer treatment and management.
  • Their flagship product, Guardant360, is FDA-approved for advanced cancer treatment decisions.
  • The company focuses on non-invasive, data-rich diagnostics to improve patient outcomes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

↓ -1%

1 year growth

↑ 0%

2 year growth

↓ -1%
NNB5
Jun 9th, 2025
Caris Life Sciences, backed by Sixth Street, targets a $5.35 billion valuation in its upcoming U.S. IPO

Competitive landscape: Caris competes with Roche's Foundation Medicine, Guardant Health, Grail, and peers like Tempus AI.

PR Newswire
Jun 4th, 2025
Leading Health Groups Launch Effort To Encourage Modernization Of Health Screening Measures

WASHINGTON, June 4, 2025 /PRNewswire/ -- A collection of public and private sector health leaders today announced a new collaboration to help ensure current health screening measures remain aligned with the rapid advancements in FDA-approved screening technologies and clinical guidelines.The Alliance for Screening Measurement Modernization (ASMM) brings together organizations from across the healthcare sector to explore a broader framework for the timely integration of evidence into currently endorsed national health screening policies."It is critically important that clinicians have what they need to keep patients healthy, including the latest diagnostics," said Lee Fleisher, M.D., M.L., ASMM chair and founder of Rubrum Advising. "The pace of technology is accelerating rapidly, but it can take more than a decade to update the quality measures that assess compliance with current health screening recommendations. This means clinicians are not incentivized to use tests that may be quicker, safer, or less invasive for patients simply because they are built on technologies that have not yet been incorporated into the latest quality measures."Over the next six months, ASMM will:Develop a replicable, transparent framework to support measure developers with timely and appropriate pathways to update currently endorsed screening quality measuresto support measure developers with timely and appropriate pathways to update currently endorsed screening quality measures Enable the evidence-based inclusion of innovative technologies that improve diagnostic speed, accuracy, and accessibilitythat improve diagnostic speed, accuracy, and accessibility Submit a consensus white paper and policy briefs to Congressional and federal agencies for considerationASMM is led by two independent but collaborative bodies: the ASMM Quality Council, whose members are guideline-setting groups and non-profit organizations, and the Industry Council, which includes organizations that are at the forefront of transforming screening technologies to support more accurate, accessible, and timely diagnoses.The Quality Council is developing the framework and will operate independently of the Industry Council, which serves as the central forum to ensure diagnostic and imaging innovators and stakeholders have a voice in the process. Together, the councils represent a range of therapeutic areas and reflect expertise in both clinical practice and quality measure development and policy.Industry Council founding members include Geneoscopy and Guardant Health and founding members of the Quality Council include ECRI, Friends of Cancer Research, Milken Institute's FasterCures, URAC, and others.SOURCE The Alliance for Screening Measurement Modernization

Insider Monkey
May 31st, 2025
Guardant Health, Inc. (GH)'s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients

Guardant Health, Inc. (NASDAQ:GH) and research collaborators have unveiled results from the largest study to date on circulating tumor DNA (ctDNA) testing in stage III colon cancer, presented at the 2025 ASCO Annual Meeting.

Guardant Health
May 27th, 2025
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test

Guardant Health introduces nearly a dozen groundbreaking Smart Liquid Biopsy applications for Guardant360 Liquid test.

Health Technology Insights
May 20th, 2025
Guardant Health Launches Hereditary Cancer Testing for Risks

Guardant Health launches Hereditary Cancer testing for risks.

INACTIVE